Advanced Oncotherapy PLC : Collaboration Agreement

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Collaboration with State University of New York's Upstate Medical University

Breakthrough agreement to bring the latest technology in radiotherapy to US patients at Syracuse, through New York State's innovative StartUp NY programme

Advanced Oncotherapy announces that it has signed a letter of intent with State University of New York ("SUNY") Upstate Medical University to establish a series of collaborative activities including a three-room proton therapy facility on its 30-acre campus in Syracuse, New York, USA.

Highlights

·     Previously, proton machines with gantries have been prohibitively expensive, and patients have had restricted access due to costs of reimbursement.

·     Advanced Oncotherapy's patented technology has cut the cost of equipment and installation by 60% compared with current technology.

·     The StartUp NY programme links academic centres with new business ventures and is designed to build on research collaborations between academia and industry. The initiative eliminates state tax for both corporations and employees for ten years.

Proton radiotherapy is at the forefront of the fight against cancer and is established as being a much more accurate form of treatment than conventional radiotherapy, causing far fewer side effects and sparing healthy tissues and organs.

Dr David Duggan, medical oncologist and dean of the College of Medicine, comments: "Affordable proton beam therapy will allow us to offer superior cancer treatment to our patients. This will be of particular importance for paediatric tumours. We will be able to mitigate many toxicities including growth delays, vision and hearing impairment as well as reduce the likelihood of secondary malignancies."

Advanced Oncotherapy's patented technology has cut the cost of equipment and installation by 60% compared with current technology.  The Company's next generation proton equipment is based on LIGHT - Linac Image Guided Hadron Technology.  LIGHT is a direct medical application of high energy particle physics research by ADAM, a spin-off company from CERN (home of the Large Hadron Collider) in Geneva, Switzerland, which Advanced Oncotherapy is in the process of acquiring.

The new proton therapy centre will support academic and research activities focused on the biology of proton treatment for cancer and its clinical utility in different types of cancers, as well as offering appropriately selected patients an affordable, more accurate and better alternative to conventional radiation therapy. Currently, SUNY Upstate treats 16,000 cancer patients annually. Since 2006, SUNY Upstate Medical University has been accredited by the American College of Surgeons' Commission on Cancer, which recognizes cancer care excellence, every year.

Advanced Oncotherapy's CEO, Dr Mike Sinclair, said, "This partnership represents a key milestone for AVO as we open the US market for affordable proton beam therapy equipment. We are very privileged to work with Dr Smith, his leadership team and Governor Cuomo to create a LIGHT demonstrator site at SUNY Upstate for FDA regulatory approval in addition to establishing a North American centre for training, assembly, marketing and distribution under the StartUp NY programme."

Dr David Smith, president of SUNY Upstate Medical University, added, "Advanced Oncotherapy is precisely the kind of business that fits well with the StartUp NY initiative and the Upstate Medical University campus," said Upstate President David R. Smith, MD. "Advanced Oncotherapy's work fits squarely into our mission of patient care, research and education, and we both share an intense focus on finding new ways to fight cancer and improve the lives of children and adults." 

For further information, please visit www.advancedoncotherapy.com or contact:

About Advanced Oncotherapy Plc ("AVO")  

1.  AVO is a provider of radiotherapy services that harnesses the best in modern technology.  As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2.  AVO is in the process of acquiring ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT.  This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3.  AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK through a number of hospitals.

About SUNY Upstate Medical University, please visitwww.upstate.edu

The region's largest employer with nearly 8,750 employees, Upstate Medical University is the only academic medical center in Central New York, serving 1.8 million people in the state from Canada to Pennsylvania with its educational, clinical and research missions.

A highlight of Upstate's leading role in the region is its ability to ensure access to vital one-of-a-kind services, such as burn and trauma care and an array of highly specialized stroke, cancer and neurosurgical and pediatric services through its 715-bed Upstate University Hospital, which includes the Upstate Golisano Children's Hospital. 

In addition to its clinical mission, Upstate, which is one of the State University of New York (SUNY)'s 64 campuses enrolls 1,600 students and offers degrees in medicine, nursing and a variety of health professions, and conducts more than $40 million in funded research.

-ends-